LG Chem Signs Strategic Collaboration with China's OTR Therapeutics
Accelerating Expansion of the Anticancer Portfolio
LG Chem announced on July 8 that it has signed a strategic collaboration agreement with the Chinese biotech innovator OTR Therapeutics (OTR Therapeutics·OTR) for the discovery and development of anticancer drug candidates.
LG Chem plans to leverage OTR's extensive network and development experience in China, which is emerging as a key hub for innovative drug development, to jointly explore, identify, and evaluate promising anticancer drug candidates from various Chinese companies. The company also aims to secure opportunities for licensing-in outstanding candidates.
Going forward, OTR will conduct preclinical and early clinical development in China, taking advantage of the country's rapid drug development environment, while LG Chem will lead global late-stage clinical development and commercialization, thereby accelerating joint development.
Jiwoong Son, Head of Life Sciences Business Division at LG Chem, said, "This collaboration with OTR is significant in that it strengthens our foundation for systematically discovering and validating promising drug candidates in China, which is emerging as a center for innovative drug development. By proactively securing promising candidates and linking them to future development opportunities, we will enhance our global competitiveness and continuously improve patient access to treatment."
Zhui Chen, founder and CEO of OTR Therapeutics, commented, "We are pleased to sign a strategic collaboration agreement that will help realize the potential of China's biotech ecosystem. By combining our agile R&D and business development capabilities with LG Chem's clinical development and commercialization expertise, we aim to transform early-stage innovations into anticancer drugs with high clinical value."
Based in Shanghai, OTR is a biotech company that integrates its own R&D and open innovation capabilities to conduct research and development in the areas of oncology, immunology and inflammatory diseases, and metabolic diseases.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
China is rapidly growing into a key ecosystem for innovative drug development, supported by government policies for new drug development and the streamlining of clinical regulations, which provide both development speed and cost competitiveness. According to the JP Morgan China biopharma report, last year, Chinese drug candidates accounted for 30% of the global innovative drug pipeline.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.